Brain scans reveal early clues to Parkinson's progression
NCT ID NCT05286736
First seen Jul 09, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This study uses advanced brain imaging and non-invasive stimulation to understand how the brain changes in the early stages of Parkinson's disease. Researchers will compare people with early Parkinson's (not yet on medication) to healthy volunteers of similar age and sex. The goal is to identify brain-based markers that could lead to earlier detection and better tracking of the disease over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could identify early brain markers that help detect Parkinson's sooner and track its progression, potentially guiding future treatments.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve symptoms. The findings may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2021
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults diagnosed with Parkinson's Disease (early diagnosis, currently untreated) and age- and sex-matched healthy controls
- Ages
-
21 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participants with PD * Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria * Not receiving levodopa or dopamine agonist to treat PD (at baseline) * Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls * Age- (+/- 3 years) and sex-matched to participants with PD * Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Exclusion Criteria: * Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent * History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment * History of bipolar disorder, post-traumatic stress disorder or major depressive disorder * Other significant neurological disorders that may affect participation or performance in the study * Implanted DBS or other neurosurgeries to treat PD * Pregnancy Additional exclusion criteria for TMS experiments (note that individuals who are excluded from the TMS experiment still have the opportunity to participate in the other data collection sessions): * History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury * Recent history of frequent syncope (fainting) episodes in response to blood, emotional stress, or sensory triggers. * Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator) * Pacemaker or any implanted device * History of surgery on blood vessels, brain, or heart * Unexplained, recurring headaches or concussion within the last six months * Severe hearing impairment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simulator-Based assessment of driving performance in patients with Parkinson's disease and multiple sclerosis
- Individualized 130 hz subthalamic temporal interference stimulation versus medication for motor symptoms in parkinson disease
- Parkinson's improvement activated by hula understanding (PAHU) - part 2
- Half a million people join quest to decode Parkinson's risk
- Can a diabetes drug slow Parkinson's? a trial puts it to the test
- Horseback therapy may help Parkinson's patients move better